Novo-nordisk-a-s

Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.

Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Is Novo Nordisk AS (NVO) a Bargain After 3.1% Drop? GF Value Says Undervalued

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Novo Nordisk (NVO) CEO Advocates for Wegovy Sales Amidst Unregulated Peptide Market

STAT+: Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more

An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Ozempic Maker Novo Nordisk's Investors Are Nervously Looking Into the Future

Novo Nordisk's chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company's…

Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsch…

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

Novo Nordisk stock is sliding again - and the Wegovy pill's surprise miss is partly to blame

The Danish drugmaker also revealed an improved outlook for the year.

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.